 |
1 Product |  |
0 Diseases | | 1 Product |
|
0 Trials |  |
9 News |  |
- | glutathione PEGylated liposomal methylprednisolone (2B3-201) / BBB Therap
P1 data, Journal: GSH-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. (Pubmed Central) - Jun 26, 2019
2B3-201 is considered safe, with no clinically relevant changes in (CNS) safety parameters and no serious adverse events. In addition, 2B3-201 shows a long plasma half-life and prolonged immunosuppressive effects.
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Feb 6, 2015
P1, N=47, Terminated, Sponsor: BBB-Therapeutics B.V.
In addition, 2B3-201 shows a long plasma half-life and prolonged immunosuppressive effects. Active, not recruiting --> Terminated
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jan 13, 2015
P1, N=54, Active, not recruiting, Sponsor: BBB-Therapeutics B.V.
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Oct 11, 2014
P1, N=54, Recruiting, Sponsor: BBB-Therapeutics B.V.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Dec 2014
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Feb 2014 --> Sep 2014
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jun 3, 2014
P1, N=48, Recruiting, Sponsor: to-BBB technologies B.V.
Trial primary completion date: Feb 2014 --> Sep 2014 N=18 --> 48
- | glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jan 27, 2014
P1, N=18, Recruiting, Sponsor: to-BBB technologies B.V.